JOINTOWN PHARMACEUTICAL GROUP
JOINTOWN PHARMACEUTICAL GROUP, a leading player in the pharmaceutical industry, is headquartered in China (CN) and operates extensively across various regions. Founded in 1995, the company has established itself as a key provider of high-quality pharmaceutical products and services, focusing on areas such as drug distribution, manufacturing, and research and development. With a diverse portfolio that includes prescription medications, over-the-counter products, and healthcare solutions, JOINTOWN stands out for its commitment to innovation and quality assurance. The company has achieved significant milestones, including strategic partnerships and expansions that enhance its market position. Recognised for its robust supply chain and comprehensive service offerings, JOINTOWN PHARMACEUTICAL GROUP continues to play a vital role in improving healthcare outcomes globally.
DitchCarbon Score
How does JOINTOWN PHARMACEUTICAL GROUP's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
JOINTOWN PHARMACEUTICAL GROUP's score of 22 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
JOINTOWN PHARMACEUTICAL GROUP's reported carbon emissions
In 2023, JOINTOWN PHARMACEUTICAL GROUP reported total carbon emissions of approximately 960,864,000 kg CO2e. This figure includes 210,819,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 677,874,000 kg CO2e from Scope 2 emissions, related to indirect emissions from the generation of purchased electricity. Additionally, Scope 3 emissions accounted for about 72,171,000 kg CO2e, which cover all other indirect emissions in the value chain. Over the years, JOINTOWN has shown fluctuations in its emissions, with a total of approximately 949,469,000 kg CO2e in 2022 and 900,112,000 kg CO2e in 2021. Notably, the company has not set specific reduction targets or climate pledges, indicating a potential area for improvement in its climate commitments. The company’s emissions intensity has decreased over time, reflecting a commitment to improving efficiency, although no formal reduction initiatives or targets have been documented. As JOINTOWN continues to operate within the pharmaceutical industry, addressing its carbon footprint will be crucial for aligning with global climate goals and enhancing sustainability practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 396,062,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 389,265,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 1,044,000 | 000,000 | 0,000,000 | 000,000 | 000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
JOINTOWN PHARMACEUTICAL GROUP is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
